Mankind Pharma Limited Announces Incorporation of Wholly Owned Subsidiary, Directly or Indirectly, in Russia and Wholly Owned Subsidiary Under Section 8 of the Companies Act, 2013
The Board of Directors of the Mankind Pharma Limited at its meeting held on April 14, 2025, has inter-alia, considered and approved the: Constitution of a ' Structural Integration Committee' to consider and evaluate various structural alternatives to integrate Bharat Serums and Vaccines Limited ("BSV") into Mankind Pharma Limited's ("Company") eco system ("Proposed Structural Integration"). A more concrete plan for the Proposed Structural Integration shall be placed before the Board of Directors of the Company for its approval in the coming months post detailed consultation of the Structural Integration Committee with the financial, legal, tax and other advisors. This will be subject to all necessary shareholder, creditor and regulatory approvals, as may be applicable; Incorporation of a wholly owned subsidiary, directly or indirectly, in Russia ("Foreign WOS"); and Incorporation of a whollyowned subsidiary under Section 8 of the Companies Act, 2013 ("Indian WOS") for undertaking CSR activities of the Mankind Group.
Mankind Pharma Limited is an India-based pharmaceutical company. It is engaged in developing, manufacturing, and marketing a range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It offers healthcare solutions for a range of healthcare needs with a portfolio that includes anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/ central nervous system, vitamins, minerals and nutrients and respiratory therapies. Its portfolio of brands includes Nurokind, Telmikind, Manforce (Rx), Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Dydroboon, Cefakind, Zenflox, Monticope, Dynaglipt, and others. Its branded product portfolio spans women’s health, fertility and critical care, with several brands in their respective therapy areas. Its subsidiaries include Lifestar Pharma Private Limited, Magnet Labs Private Limited, Jaspack Industries Private Limited, and others.
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Mankind Pharma Limited Announces Incorporation of Wholly Owned Subsidiary, Directly or Indirectly, in Russia and Wholly Owned Subsidiary Under Section 8 of the Companies Act, 2013
